New insider activity at Medpace Holdings ( (MEDP) ) has taken place on December 1, 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CEO August J. Troendle has recently sold 56,482 shares of Medpace Holdings stock, amounting to a significant transaction worth $34,074,469.
Recent Updates on MEDP stock
BMO Capital initiated coverage of Medpace Holdings with a Market Perform rating, citing the stock’s full valuation amidst a “tepid” biotech funding environment. The firm expressed concerns about the limited buffer for potential macroeconomic volatility at current share levels. This assessment reflects broader market conditions and the specific financial landscape affecting biotech investments.
Spark’s Take on MEDP Stock
According to Spark, TipRanks’ AI Analyst, MEDP is a Outperform.
Medpace Holdings demonstrates strong financial performance and positive earnings call sentiment, which are the most significant factors driving the score. Technical analysis indicates strong momentum but also suggests caution due to overbought conditions. The high P/E ratio impacts the valuation score, reflecting potential overvaluation concerns.
To see Spark’s full report on MEDP stock, click here.
More about Medpace Holdings
YTD Price Performance: 76.99%
Average Trading Volume: 313,031
Technical Sentiment Signal: Buy
Current Market Cap: $16.69B